#ANIX

3 days ago

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar is featured on the Water Tower Research Healthcare Happenings podcast on March 12, 2026. Dr. Kumar discusses positive clinical trial data for the breast cancer vaccine and ovarian cancer CAR-T therapy, plus future plans and the company's financial condition. The podcast is available at the Water Tower Research media page.

#ANIX Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

PenkeTrading

@penkeinvesting.bsky.social

4 days ago

Fundamental analysis of $ANIX (Anixa Biosciences Inc) based on financial data and reported results.

#ANIX

0 0 0 0

StockTitan

@stocktitan.net

6 days ago

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology Anixa Biosciences (NASDAQ: ANIX) announced the Korean Ministry of Intellectual Property issued a Notice of Allowance for a patent titled "Vaccine Adjuvants and Formulations" covering its breast cancer vaccine technology, licensed exclusively from Cleveland Clinic.The allowance expands international IP coverage, complements U.S. patents, and follows a Phase 1 trial that was safe, met primary endpoints, and generated immune responses in 74% of participants, supporting further clinical development and potential future commercialization outside the U.S.

#ANIX Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic Anixa Biosciences (NASDAQ: ANIX) announced completion of the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine from Cleveland Clinic and is now the trial sponsor for future development.Enrollment was completed in Phase 1 with encouraging immune response and safety data, and Anixa plans to advance the vaccine into a Phase 2 clinical trial using multiple clinical sites, including Cleveland Clinic. The vaccine targets α-lactalbumin, a lactation-associated protein re-expressed in many breast cancers. Phase 1 findings were presented on December 11, 2025 at the San Antonio Breast Cancer Symposium.

#ANIX Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

Cancer-Vaccine

@cancer-vaccine.activitypub.awakari.com.ap.brid.gy

3 months ago

Original post on benzinga.com

Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why Anixa Biosciences shares surged in after-hours trading after presenting clinical trial data for its investigational ...

#ANIX #Equities #News #why #it's #moving #Health #Care […]

[Original post on benzinga.com]

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants Anixa Biosciences (NASDAQ: ANIX) announced final Phase 1 data for its investigational α-lactalbumin (aLA) breast cancer vaccine presented at SABCS on Dec 11, 2025. The trial enrolled 35 participants across three cohorts and met all major primary endpoints. The vaccine was safe and well tolerated at the maximum tolerated dose (MTD), eliciting protocol-defined immune responses in 74% of participants. Combination dosing with pembrolizumab (Keytruda) generated antigen-specific T cell responses with no major additional side effects. Results support advancing to a planned Phase 2 neoadjuvant combination study; participants will be followed for five years. Data were collected in collaboration with Cleveland Clinic and funded by a U.S. Department of Defense grant.

#ANIX Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic Anixa Biosciences (NASDAQ: ANIX) executed a data transfer agreement (DTA) with Cleveland Clinic on Nov. 5, 2025 to move Phase 1 breast cancer vaccine clinical data and support transfer of the IND sponsorship to Anixa.The company says Phase 1 enrollment is complete and showed encouraging immune response signals; Anixa plans to assume full IND sponsorship and advance the vaccine into a Phase 2 trial. Final Phase 1 data will be presented at the San Antonio Breast Cancer Symposium on Dec. 11, 2025.

#ANIX Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology Anixa Biosciences (NASDAQ: ANIX) announced that the Chinese National Intellectual Property Administration issued Patent No. ZL2020800215666, covering key aspects of its breast cancer vaccine technology and extending IP protection in China into the 2040s.The vaccine, invented at Cleveland Clinic and exclusively licensed to Anixa, targets human α-lactalbumin to prevent and treat certain breast cancers. Anixa said this patent strengthens its global patent estate and supports future international development and commercialization. A Phase 1 trial has been completed and full results will be presented on Dec 11, 2025 at the San Antonio Breast Cancer Symposium.

#ANIX Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

Judy Fitzgerald

@jfbcadvocate.bsky.social

5 months ago

Press Releases :: Anixa Biosciences, Inc. (ANIX)

A long road but an amazing beginning...

ir.anixa.com/press-releas...

#ANIX #breastcancervaccine #pinkvaccine #preventionisthecure

0 0 0 0

Oninvest

@oninvest.bsky.social

5 months ago

Freedom Broker initiates on biotech Anixa with 'buy' at TP implying 177% upside – Oninvest The fair value of micro-cap biotech Anixa Biosciences, which is developing, among other projects, a cancer vaccine, is almost three times higher than the current share price, Freedom Broker estimates....

🧬Freedom Broker initiated coverage on #ANIX with a Buy rating and a $9 target, implying ~177% upside. Analysts cite early success in cancer vaccine and CAR-T trials, strong institutional partnerships, and low cash burn as key strengths. More: en.oninvest.com/article/free...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial Anixa Biosciences (NASDAQ: ANIX) announced completion of the final patient visit in its Phase 1 breast cancer vaccine trial on Oct 7, 2025. The study enrolled 35 women across three cohorts: 26 in triple-negative breast cancer (TNBC), 4 in a prevention cohort, and 5 given pembrolizumab concurrently. The trial is fully funded by a U.S. Department of Defense grant and the vaccine was invented in partnership with Cleveland Clinic.Preliminary findings reported >70% of participants showed protocol-defined immune responses. Sample collection is complete; a final study report will be submitted to the Department of Defense, a Clinical Study Report will be filed with the FDA, and Cleveland Clinic will present full results at the San Antonio Breast Cancer Symposium on Dec 11, 2025.

#ANIX Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival Anixa Biosciences (NASDAQ: ANIX) has completed dosing the fourth cohort in its Phase 1 clinical trial for a novel FSHR-targeted CAR-T therapy treating recurrent ovarian cancer. The fourth cohort received 3×10⁶ CAR-positive cells per kilogram, a 30-fold increase from the first cohort, with no dose-limiting toxicities observed.Several treated patients have surpassed median survival expectations, with one patient from the first cohort remaining alive 28 months post-treatment. The fifth cohort is planned to receive approximately 1×10⁷ cells/kg following a 30-day safety review. The therapy targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, tumor vasculature, and certain cancer cells.

#ANIX Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Leading Cancer Treatment Biotech Anixa Biosciences Set for Key Presentation at Global Investment Conference Anixa Biosciences CFO Mike Catelani to present at H.C. Wainwright Global Investment Conference on Sept 9 at 10:30 AM ET. One-on-one meetings available in New York City.

#ANIX Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

First-Ever Chinese Patent Granted: Anixa's Revolutionary Breast Cancer Vaccine Targets World's Largest Market Biotech firm Anixa receives Notice of Allowance from CNIPA for breast cancer vaccine technology, expanding IP protection in China through 2040s. Technology targets α-lactalbumin protein.

#ANIX Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

30x Dose Increase Shows No Toxicity: Anixa's Novel Ovarian Cancer CAR-T Therapy Reaches Major Milestone Biotech firm Anixa advances Phase 1 ovarian cancer CAR-T trial with 3M cells/kg dose - 30x initial level. No toxicity observed in fourth cohort. Targets FSHR in recurring cases after 2+ therapies.

#ANIX Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

Spanish open dictionary

@wordmeaningdic.bsky.social

6 months ago

Meaning of #anix It is another name given to an umbelliferous plant. It is the plant with the scientific name Pimpinella anisum of the Apiaceae family. It is also known as pimpernella, anise, matalahuba, matalahuga. .. anix

0 0 0 0

Dicionário colaborativo Espanhol

@ptsignificadode.bsky.social

6 months ago

Significado de #anix É outro nome dado a uma planta umbelífera. É a planta com o nome científico Pimpinella anisum da família Apiaceae. Também é conhecido como pimpernella, anis, matalahuba, matalahuga. .. anix

0 0 0 0

Diccionario Abierto

@significadode.bsky.social

6 months ago

Significado de #anix Es otro de los nombres que recibe una planta umbelífera. Se trata de la planta de nombre científico Pimpinella anisum de la familia Apiaceae. También se le conoce como pimpinela, anís, matalahuba, matalahuga. .. anix

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Breakthrough: Anixa Secures 20+ Year Patent Protection for Revolutionary Solid Tumor CAR-T Technology Latest patent strengthens Anixa's exclusive CAR-T platform for solid tumors, including ovarian cancer. Currently in clinical trials at Moffitt Cancer Center. See trial updates.

#ANIX Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Breakthrough CAR-T Therapy for Ovarian Cancer: Moffitt's Chair Reveals Latest Trial Progress at Major Conference Principal investigator Dr. Wenham shares Phase 1 CAR-T therapy insights at Ovarcoming Cancer Conference. Learn latest immunotherapy advances. Get trial updates.

#ANIX Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

7 months ago

NASDAQ: #ANIX
#AnixaBio moves closer to a Phase 2 trial for its breast cancer vaccine after positive Phase 1 results, taking over the IND from Cleveland Clinic.
prismmarketview.com/anixa-biosci...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Breakthrough Breast Cancer Vaccine Achieves 70% Immune Response, FDA Clears Path for Phase 2 Trial Novel breast cancer vaccine targeting α-lactalbumin protein demonstrates strong immune response in Phase 1. FDA approves IND transfer for expanded Phase 2 trial. See results.

#ANIX Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

First-Ever Breast Cancer Prevention Vaccine Technology Expands Global Patent Protection in Canada Novel immunogenic approach targets breast cancer prevention. Exclusive Cleveland Clinic technology expands to Canadian market. See breakthrough details.

#ANIX Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

www.stocktitan.net/news/ANIX/anixa-bioscien...

0 0 0 0

Posts tagged #ANIX